General practice. Abstract. Subjects and methods. Introduction. examining the effect of use of oral contraceptives on mortality in the long term.

Transcription

1 Mortality associated with oral contraceptive use: 25 year follow up of cohort of women from Royal College of General Practitioners oral contraception study Valerie Beral, Carol Hermon, Clifford Kay, Philip Hannaford, Sarah Darby, Gillian Reeves Editorial by Skegg Imperial Cancer Research Fund, Cancer Epidemiology Unit, Radcliffe Infirmary, Oxford OX2 6HE Valerie Beral, Carol Hermon, scientific officer Sarah Darby, Gillian Reeves, statistician Royal College of General Practitioners, Manchester Research Unit, Parkway House, Manchester M22 4DB Clifford Kay, director Philip Hannaford, Correspondence to: Professor Beral BMJ 1999;318: Abstract Objective To describe the long term effects of the use of oral contraceptives on mortality. Design Cohort study with 25 year follow up. Details of oral contraceptive use and of morbidity and mortality were reported six monthly by general practitioners. 75% of the original cohort was flagged on the NHS central registers. Setting 1400 general practices throughout Britain. Subjects women, half of whom were using oral contraceptives at recruitment in Median age at end of follow up was 49 years. Main outcome measures Relative risks of death adjusted for age, parity, social class, and smoking. Results Over the 25 year follow up 1599 were reported. Over the entire period of follow up the risk of death from all causes was similar in ever users and never users of oral contraceptives (relative risk = 1.0, 95% confidence interval 0.9 to 1.1; P = 0.7) and the risk of death for most specific causes did not differ significantly in the two groups. However, among current and recent (within 10 years) users the relative risk of death from ovarian cancer was 0.2 (0.1 to 0.8; P = 0.01), from cervical cancer 2.5 (1.1 to 6.1; P = 0.04), and from cerebrovascular disease 1.9 (1.2 to 3.1, P = 0.009). By contrast, for women who had stopped use >10 years previously there were no significant excesses or deficits either overall or for any specific cause of death. Conclusion Oral contraceptives seem to have their main effect on mortality while they are being used and in the 10 years after use ceases. Ten or more years after use ceases mortality in past users is similar to that in never users. Introduction Oral contraceptives have been available for 40 years and, although their short term effects on health have been studied in detail, 12 comparatively little is known about whether these effects persist after use stops. The Royal College of General Practitioners oral contraception study was set up in 1968 to monitor the health of women who had used oral contraceptives. We present the results of a 25 year follow up of that population examining the effect of use of oral contraceptives on mortality in the long term. Subjects and methods Over 14 months from May 1968, 1400 general practitioners throughout the United Kingdom recruited women who were using oral contraceptives and a similar number who had never used them into the oral contraception study. 1 Most women (98%) were white and all were married or living as married. General practitioners were asked to provide information on oral contraceptives prescribed, pregnancies, new illness, or death for each subject every six months. During the early years of the study some general practitioners withdrew their patients and some women moved and left the study. In an attempt was made to flag the cohort on the NHS central registers in Southport and Edinburgh to provide information on death and cause of death for women who were no longer being followed regularly by their general practitioner. About 75% of the original cohort was successfully flagged, and these women have been followed for death and emigration since then. The remaining 25% could not be flagged because they or their general practitioners had left the study before the flagging procedure could be instigated and the personal details required for flagging were not available to the investigators. The mortality of the women who were followed regularly by their general practitioner was similar to that of women who left the study. 3 This analysis includes up to 31 December We obtained a copy of the death certificate for all women who had died, and CK or PH coded the cause of death according to ICD-8 (international classification of diseases, eighth revision), 4 occasionally supplementing information from the death certificate with details provided by general practitioners. 5 Personyears of follow up were calculated from the date of recruitment up to the date of death for the 1599 women who had died, up to the date of last contact with the general practitioner for women who were not flagged on the NHS registers, or up to 31 December 1993 for women who were flagged on the NHS registers and alive on that date. 3 For women who were no longer being followed by their general practitioner before 1 January 1977 but were 96 BMJ VOLUME JANUARY

2 flagged no person-years were included for the period between the date of last contact with their general practitioner and 1 January 1977 because the ascertainment of during that period may have been incomplete. 3 Person-years were categorised by age (16-19, ), parity (0, 1-2, >3, not known), social class at recruitment (I-II, III, IV-V, other), and cigarette smoking at recruitment (0, 1-14/day, >15/day, not known) with a standard computer program. 6 Personyears were further subdivided according to whether the women had taken oral contraceptives and, where appropriate, by duration of use and time since first and last use. At recruitment half (23 000) of the subjects were using oral contraceptives, but by 31 December 1993, 63% had used them at some time. Women who started using oral contraceptives after recruitment contributed person-years to the never user category up to the date that they began using them. For women who were flagged on the NHS registers but no longer regularly followed up by their general practitioner, we assumed that past users and never users who were over the age of 40 at the date of last contact did not subsequently take oral contraceptives. For current users and women aged under 40 at the time of last contact with their general practitioners, we assumed that use continued for two years as stated at the time of last contact, but thereafter use was classified as unknown. These assumptions about subsequent use of oral contraceptives are similar to those used in analyses of other cohort studies. 7 The results presented here are based on person-years of follow up until 31 December 1993: in women who had used oral contraceptives and in women who had never used them. Standardised mortality ratios were calculated by using mortality for women in England and Wales as a standard. 6 Relative risks were adjusted for age, parity, social class, and smoking with the Poisson regression program module of epicure. 8 P values are two tailed. Results By 31 December 1993 the cohort had been followed for 25 years and the median age of the women was 49 years (48 for ever users of oral contraception and 50 for never users). During that period 1599 were reported, 945 in ever users and 654 in never users (table 1). The death rate from all causes combined was 21% lower than in the UK population (overall standardised mortality ratio = 79). The relative risk of death from all causes combined after adjustment for age, parity, social class, and cigarette smoking did not differ significantly between ever users and never users (relative risk = 1.0, 95% confidence interval 0.9 to 1.1; P = 0.7). Table 1 also shows standardised mortality ratios and adjusted relative risks of death for common specific causes and groups of causes of death (and also for some particular causes that have been reported to be affected by oral contraceptive use) according to ever use of oral contraceptives. For most specific causes of death the standardised mortality ratios in ever users and never users of oral contraceptives were around 100 and did not differ significantly between the two groups. The few exceptions were colorectal cancer and Table 1 Standardised mortality ratios in ever users and never users of oral contraceptives and relative risk in ever users compared with never users Standardised mortality ratio ( ) Ever users Never users All causes ( ) 82 (945) 74 (654) 1.0 (0.9 to 1.1) All cancers ( ) 85 (474) 85 (355) 1.0 (0.8 to 1.1) Colorectal ( ) 62 (29) 108 (39) 0.6 (0.4 to 0.9)* Liver (155) 126 (5) 34 (1) 5.0 (0.6 to 43.2) Lung (162) 107 (75) 71 (40) 1.2 (0.8 to 1.8) Breast (174) 87 (154) 81 (105) 1.1 (0.8 to 1.4) Cervix (180) 115 (38) 57 (13) 1.7 (0.9 to 3.2) Uterus (181-2) 22 (2) 83 (6) 0.3 (0.1 to 1.4) Ovary (183) 49 (24) 83 (31) 0.6 (0.3 to 1.0)* Other cancers 87 (147) 95 (120) 0.9 (0.7 to 1.1) All circulatory diseases ( ) 84 (237) 63 (143) 1.2 (1.0 to 1.5) Ischaemic heart disease (410-4) 70 (98) 68 (79) 0.9 (0.7 to 1.3) Other heart disease (420-9) 107 (19) 66 (9) 1.4 (0.6 to 3.1) Cerebrovascular disease (430-8) 111 (87) 62 (38) 1.5 (1.0 to 2.3)* Other circulatory 73 (33) 46 (17) 1.4 (0.8 to 2.5) All digestive diseases (520-77) 85 (37) 74 (24) 1.1 (0.6 to 1.8) Liver disease (570-3) 112 (23) 69 (10) 1.7 (0.8 to 3.6) All other diseases (1-139, , , 53 (95) 65 (89) 0.8 (0.6 to 1.0) Violent or accidental causes ( ) 111 (102) 68 (43) 1.6 (1.1 to 2.3)* Suicide (950-9) 123 (39) 73 (16) 1.5 (0.8 to 2.7) *P<0.05. Adjusted for age, social class, parity, and smoking. ovarian cancer, for which the relative risks of death in users were significantly below 1.0, and cerebrovascular disease and all violent and accidental causes of death, for which the relative risks were significantly greater than 1.0. Ever use is, however, a crude measure of use of oral contraceptives. Table 2 shows for various causes the relative risk of death compared with never users in relation to the number of years since oral contraceptives were first used. Within the first 10 years of starting use of oral contraceptives there was a significant excess mortality from all causes of death (relative risk = 1.2, 95% confidence interval 1.0 to 1.50; P = 0.03), all circulatory diseases (2.2, 1.5 to 3.2; P < ), and cerebrovascular disease (2.7, 1.5 to 4.9; P = ). However, the excess mortality from these causes fell with time, this trend being significant for all circulatory disease (P = 0.002) and cerebrovascular disease (P = 0.02). There were 380 in women who began using oral contraceptives more than 20 years before the end of follow up, and this group showed no significant excess or deficit in mortality from any specific condition or overall. Table 3 shows the pattern of risk of death for various conditions in relation to the time since stopping use of oral contraceptives. By the end of follow up the median time since last use in the cohort was 17 years. Significant increases or decreases in risk were found mainly in current users or those who had stopped use within the past 10 years for example, women who were current users or who stopped use in the past five years had a significantly reduced risk of ovarian cancer (0.1, 0.0 to 0.9; P = 0.04) and a significant excess of all circulatory diseases (1.7, 1.2 to 2.4; P = 0.006) and cerebrovascular disease (1.9, 1.1 to 3.4; P = 0.03) and women who had stopped use five to nine years previously had an significant excess risk of cervical cancer (3.0, 1.1 to 8.1; P = 0.03) and cerebrovascular disease (2.0, 1.1 to 3.7; P = 0.02). Among women who had stopped use 15 or more years previously most of BMJ VOLUME JANUARY

3 Table 2 Relative risk of death in users of oral contraceptives compared with never users according to time since first use Years since first use of oral contraceptives < >20 test for trend by time since first use All causes ( ) 1.2 (1.0 to 1.5)* (0.9 to 1.2) (0.8 to 1.1 ) All cancers ( ) 0.9 (0.7 to 1.3) (0.8 to 1.2) (0.8 to 1.1 ) Colorectal ( ) 0.7 (0.2 to 2.2) (0.3 to 1.1) (0.3 to 1.1 ) Lung (162) 0.9 (0.3 to 2.3) (0.8 to 2.1) (0.7 to 1.9 ) Breast (174) 1.1 (0.7 to 1.8) (0.9 to 1.6) (0.7 to 1.3 ) Cervix (180) 0.8 (0.3 to 2.5) (1.00 to 4.0) (0.8 to 4.2 ) Ovary (183) 0.9 (0.3 to 2.7) (0.2 to 1.0)* (0.3 to 1.3 ) Other cancers 1.0 (0.6 to 1.6) (0.7 to 1.2) (0.7 to 1.2 ) All circulatory diseases ( ) 2.2 (1.5 to 3.2)** (1.0 to 1.7) (0.7 to 1.2 ) Ischaemic heart disease ( ) 1.8 (1.0 to 3.2) (0.7 to 1.6) (0.5 to 1.1 ) Other heart disease ( ) 2.1 (0.5 to 9.3) (0.6 to 4.5) (0.4 to 3.0) Cerebrovascular disease ( ) 2.7(1.5 to 4.9)** (1.1 to 2.7)* (0.6 to 1.8 ) Other circulatory 2.4 (0.9 to 6.5) (0.6 to 2.7) (0.6 to 2.5 ) All digestive diseases ( ) 1.2 (0.5 to 3.0) (0.7 to 2.4) (0.4 to 1.8 ) Liver disease ( ) 2.0 (0.6 to 7.0) (0.6 to 3.7) (0.7 to 4.4 ) All other diseases (1-139, , , 0.9 (0.5 to 1.6) (0.4 to 0.9)* (0.6 to 1.3 ) Violent and accidental causes ( ) 1.6 (1.0 to 2.7) (1.0 to 2.3) (1.0 to 2.7 ) Suicide ( ) 1.9 (0.9 to 4.1) (0.7 to 2.8) (0.4 to 2.9) *P<0.05,**P<0.01. Adjusted for age, parity, social class, and smoking. the relative risks were around 1.0. For ovarian cancer there was a weak suggestion that the protective effect associated with current or recent use wore off (test for trend, P = 0.05). Among ever users of oral contraceptives, the average duration of use was five years. Table 4 shows the relative risk of death in relation to the duration of use of oral contraceptives. Women who used oral contraceptives for 10 or more years had a significant excess mortality from lung cancer (2.0, 1.1 to 3.5; P = 0.02) and cervical cancer (4.1, 1.6 to 10.6; P = 0.003). The excess from lung cancer were mainly among smokers (17 in smokers and three in non-smokers), the relative risk associated with 10 or more years of use of oral contraceptives being 2.0 for smokers and 2.2 for non-smokers. This excess may be a chance finding or perhaps due to residual confounding. There was also a significant trend of increasing mortality for all cancers combined and for cervical cancer in relation to duration of use (P = 0.02 and 0.03, respectively). and time since first and last use of oral contraceptives were highly correlated, with current and recent users being more likely to have used contraceptives for longer. Table 5 shows the relative risk of death among ever users of oral contraceptives according to time since last use of oral contraceptives and duration of use. All significant results were confined to women currently using oral contraceptives or who had stopped in the past 10 years, although Table 3 Relative risk of death in users of oral contraceptives compared with never users according to time since last use Years since last use of oral contraceptives Current and < >15 test for trend by time since Cause of death (ICD-8 codes) last use All causes ( ) 1.0 (0.9 to 1.2) (0.9 to 1.3 ) (0.9 to 1.3) (0.8 to 1.1) All cancers ( ) 0.9 (0.7 to 1.1) (0.8 to 1.4) (0.8 to 1.3) (0.7 to 1.1) Colorectal ( ) 0.5 (0.2 to 1.4) (0.2 to 1.6) (0.1 to 0.8)* (0.5 to 2.0) Lung (162) 0.8 (0.3 to 1.7) (0.6 to 2.2) (0.8 to 2.4) (0.6 to 2.1) Breast (174) 1.0 (0.6 to 1.6) (1.0 to 2.2) (0.8 to 1.9) (0.6 to 1.5) Cervix (180) 2.2 (0.8 to 6.1) (1.1 to 8.1)* (0.5 to 4.9) (0.1 to 3.2) Ovary (183) 0.1 (0.0 to 0.9)* (0.1 to 1.4) (0.3 to 1.8) (0.3 to 1.7) Other cancers 1.0 (0.6 to 1.6) (0.6 to 1.4) (0.7 to 1.6) (0.6 to 1.2) All circulatory diseases ( ) 1.7 (1.2 to 2.4)** (0.9 to 2.0) (0.8 to 1.7) (0.7 to 1.4) Ischaemic heart disease ( ) 1.5 (0.8 to 2.8) (0.3 to 1.4) (0.6 to 1.6) (0.6 to 1.6) Other heart disease ( ) 2.4 (0.6 to 9.7) (0.9 to 10.7) (0.2 to 3.4) (0.3 to 3.0) Cerebrovascular disease ( ) 1.9 (1.1 to 3.4)* (1.1 to 3.7)* (0.8 to 2.6) (0.5 to 1.9) Other circulatory 1.8 (0.6 to 4.9) (0.6 to 4.9) (0.7 to 4.3) (0.2 to 2.2) All digestive diseases ( ) 1.1 (0.4 to 2.7) (0.4 to 2.9) (0.6 to 3.3) (0.3 to 2.1) Liver disease ( ) 1.3 (0.4 to 4.6) (0.6 to 6.9) (0.5 to 6.1) (0.5 to 5.8) All other diseases (1-139, , , 0.6 (0.3 to 1.1) (0.3 to 1.1) (0.5 to 1.3) (0.5 to 1.3) Violent and accidental causes ( ) 1.3 (0.8 to 2.1) (0.7 to 2.6) (0.8 to 2.8) (0.8 to 3.1) Suicide ( ) 1.4 (0.6 to 3.0) (0.6 to 3.9) (0.4 to 3.7) (0.3 to 4.5) *P<0.05, **P<0.01. Adjusted for age, parity, social class, and smoking. 98 BMJ VOLUME JANUARY

4 Table 4 Relative risk of death in users of oral contraceptives compared with never users according to duration of use Duration of oral contraceptive use (years) <5 5-9 >10 test for trend with duration of use All causes ( ) 1.0 (0.9 to 1.1) (0.9 to 1.2) (0.9 to 1.3) All cancers ( ) 0.9 (0.7 to 1.1 ) (0.7 to 1.1) (1.0 to 1.6) Colorectal ( ) 0.6 (0.3 to 1.2) (0.4 to 1.6) (0.1 to 1.2) Lung (162) 1.1 (0.6 to 1.8) (0.4 to 1.4) (1.1 to 3.5)* Breast (174) 1.1 (0.8 to 1.6) (0.7 to 1.5) (0.9 to 2.1) Cervix (180) 1.3 (0.5 to 3.4) (0.5 to 4.0) (1.6 to 10.6)** Ovary (183) 0.5 (0.2 to 1.2) (0.3 to 1.5) (0.0 to 1.3) Other cancers 0.8 (0.6 to 1.1) (0.7 to 1.4) (0.8 to 1.8) All circulatory diseases ( ) 1.2 (0.9 to 1.6) (1.0 to 1.8) (0.7 to 1.6) Ischaemic heart disease ( ) 1.0 (0.7 to 1.6) (0.7 to 1.7) (0.5 to 1.6) Other heart disease ( ) 1.2 (0.4 to 3.3) (0.8 to 5.7) (0.1 to 4.2) Cerebrovascular disease ( ) 1.5 (0.9 to 2.3) (1.0 to 2.9)* (0.7 to 2.6) Other circulatory 1.5 (0.7 to 3.2) (0.5 to 3.0) (0.4 to 4.2) All digestive diseases ( ) 1.1 (0.5 to 2.2) (0.4 to 2.2) (0.4 to 3.3) Liver disease ( ) 1.4 (0.5 to 3.8) (0.4 to 4.7) (1.0 to 9.5) All other diseases (1-139, , , 0.8 (0.5 to 1.1) (0.5 to 1.2) (0.3 to 1.1) Violent and accidental causes ( ) 1.4 (0.9 to 2.1) (0.8 to 2.3) (0.7 to 2.9) Suicide ( ) 1.1 (0.5 to 2.4) (0.8 to 3.9) (0.5 to 4.5) *P<0.05, **P<0.01. Adjusted for age, parity, social class, and smoking. among such women duration of use was not associated with a significant increase or decrease in mortality from any particular cause or overall. Women who stopped using oral contraceptives 10 or more years previously had no significant increases or decreases in relative risk of death from any cause, even if they had used them for 10 years or more. There were, however, only 54 in this subgroup. Discussion Our results suggest that most of the effects of oral contraceptives on mortality occur in current or recent users and that few, if any, effects persist 10 years after stopping use. These results relate predominately to use of combined oral contraceptives containing 50 μg oestrogen. 1 Information on use of oral contraceptives was recorded prospectively at six monthly intervals by the subjects general practitioner and so is unlikely to be biased by subsequent events. Furthermore, because three quarters of the original cohort was flagged on the NHS central registers in England and Scotland and so followed routinely for death, the findings are likely to be representative of the majority of the women originally recruited. Mortality was similar in women Table 5 of death in users of oral contraceptives compared with never users according to time since last use and duration of use Current users or last use <10 years previously <10 years ( ) >10 years ( ) Last use >10 years previously <10 years ( ) >10 years ( ) All users All users All causes ( ) 1.0 (0.9 to 1.2) 1.0 (254) 1.1 (87) 1.0 (0.9 to 1.1) 1.0 (331) 1.1 (54) All cancers ( ) 1.0 (0.8 to 1.2) 0.8 (104) 1.3 (56) 1.0 (0.8 to 1.2) 1.0 (171) 1.2 (32) Colorectal ( ) 0.5 (0.2 to 1.2) 0.5 (6) 0.5 (2) 0.6 (0.3 to 1.2) 0.7 (14) 0.0 (0) Lung (162) 0.9 (0.5 to 1.7) 0.6 (9) 1.6 (10) 1.2 (0.8 to 2.0) 1.1 (27) 2.6 (10) Breast (174) 1.2 (0.8 to 1.7) 1.1 (40) 1.5 (19) 1.1 (0.8 to 1.5) 1.1 (51) 1.1 (7) Cervix (180) 2.5 (1.1 to 6.1)* 1.6 (9) 5.3 (8) 1.1 (0.4 to 3.1) 1.2 (6) 1.5 (1) Ovary (183) 0.2 (0.1 to 0.7)* 0.2 (2) 0.3 (1) 0.7 (0.4 to 1.4) 0.8 (12) 0.0 (0) Other cancers 0.9 (0.7 to 1.3) 0.9 (38) 1.1 (16) 0.9 (0.7 to 1.3) 0.9 (61) 1.3 (14) All circulatory diseases( ) 1.5 (1.1 to 2.0)** 1.7 (76) 1.1 (16) 1.1 (0.8 to 1.4) 1.1 (85) 1.0 (12) Ischaemic heart disease ( ) 1.0 (0.6 to 1.7) 1.2 (21) 0.7 (5) 1.0 (0.7 to 1.5) 1.0 (42) 1.1 (7) Other heart disease ( ) 2.8 (0.9 to 8.4) 3.5 (7) 1.3 (1) 0.9 (0.3 to 2.4) 1.0 (7) 0.0 (0) Cerebrovascular disease ( ) 1.9 (1.2 to 3.1)* 2.1 (36) 1.5 (8) 1.2 (0.7 to 2.0) 1.2 (26) 1.0 (3) Other circulatory 1.7 (0.7 to 3.9) 1.8 (12) 1.2 (2) 1.2 (0.5 to 2.7) 1.1 (10) 1.5 (2) All digestive diseases ( ) 1.0 (0.5 to 2.2) 0.9 (9) 1.5 (4) 1.1 (0.5 to 2.2) 1.1 (12) 0.7 (1) Liver disease ( ) 1.6 (0.6 to 4.4) 1.0 (4) 3.6 (4) 1.7 (0.6 to 4.7) 1.8 (7) 1.9 (1) All other diseases (1-139, , , 0.6 (0.4 to 1.0)* 0.7 (25) 0.4 (4) 0.8 (0.6 to 1.2) 0.8 (41) 0.8 (6) Violent and accidental causes ( ) 1.3 (0.8 to 2.0) 1.3 (40) 1.4 (7) 1.5 (0.9 to 2.6) 1.5 (22) 1.8 (3) Suicide ( ) 1.4 (0.7 to 2.9) 1.4 (19) 1.3 (3) 1.2 (0.5 to 3.1) 1.1 (6) 1.9 (1) *P<0.05,**P<0.01. Adjusted for age, parity, social class, and smoking. No significant differences in relative risk were found between women who used oral contraceptives for <10 and >10 years. BMJ VOLUME JANUARY

5 who remained under regular follow up by their general practitioner and in women who did not. 3 That overall mortality in our cohort was about 20% below the national average is not unexpected since women with severe chronic illnesses were not recruited. 13 Death certificates were obtained for all women who died. There was good agreement between cause of death recorded on the death certificate and that reported by general practitioners. 5 We adjusted for the potential confounding factors of age, parity, social class, and cigarette smoking. Information on age and parity was updated throughout the follow up, whereas social class and smoking details were recorded at entry only. Information on subsequent smoking habits was obtained in for members of the original cohort; re-estimation of the risk of myocardial infarction associated with oral contraceptive use based on the updated data gave virtually identical results to those based on smoking history at entry. 9 Use of information on smoking at entry is thus unlikely to have biased our results. We did not adjust for hypertension or other heart disease because such conditions could be in the causal pathway for death from circulatory diseases. No data on family history of these conditions or of cancer were available, but the absence of such information is unlikely to produce spurious associations suggesting that mortality varies according to the timing of oral contraceptive use. The specific diseases showing significant excesses or deficits in mortality in our study were generally consistent with the results of other studies on the incidence of these diseases Other cohort studies have reported no significant changes in mortality among women who have ever used oral contraceptives, which might at first sight be interpreted as inconsistent with their known effects on incidence of disease. What our results highlight, however, is that the effects of oral contraceptives on mortality occur mainly in current and recent users. The effects of oral contraceptives on circulatory diseases are already recognised to be largely confined to current users, especially if they also smoke There has been concern, however, that oral contraceptive use might affect risk of cancer many years after use stops. The collaborative reanalysis of the worldwide data on the relation between breast cancer and oral contraceptive use, which included data from this study, showed that the incidence of breast cancer was slightly increased while women used oral contraceptives and in the 10 years after stopping use but that there was no excess risk 10 or more years after stopping. 7 Our results are consistent with this finding and suggest that other cancers of the female reproductive organs may also be affected by current and recent use of oral contraceptives but may wear off after use stops. The number of from each type of cancer was small, and further data are needed to confirm our findings. Continued follow up of this and other cohorts will yield important information for the many millions of women throughout the world who have used oral contraceptives. We thank the 1400 doctors who have contributed data to the study. Contributors: CK set up the oral contraception study and PH took over as director in CH, SD, GR, and VB contributed to the data analysis. VB prepared the first draft of the manuscript and all other authors have contributed to it. CK is guarantor for the quality of the data; VB and CH are guarantors for the analyses and text. Funding: Royal College of General Practitioners, British Heart Foundation, Imperial Cancer Research Fund, Medical Insurance Agency, Medical Research Council, Schering AG (Berlin), Schering Health Care (UK), Searle, and Wyeth-Ayerst International (USA). Competing interests: None declared. 1 Royal College of General Practitioners. Oral contraceptives and health. London: Pitman Medical, Vessey M, Doll R, Peto R, Johnson B, Wiggins P. A long-term follow-up study of women using different methods of contraception an interim report. J Biosoc Sci 1976;8: Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G. Mortality in relation to method of follow up in the Royal College of General Practitioners oral contraception study. In: Hannaford PS, Webb AMC, eds. Evidence-guided prescribing of the pill. London: Parthenon Publishing, 1996: World Health Organisation. International classification of diseases, injuries and causes of death: 8th revision, Geneva: WHO, Wingrave SJ, Beral V, Adelstein AM, Kay CR. Comparison of cause of death coding on death certificates with coding in the Royal College of General Practitioners oral contraception study. J Epidemiol Community Health 1981;35: Coleman M, Douglas A, Hermon C, Peto J. Cohort study analysis with a FORTRAN computer program. Int J Epidemiol 1986;15: Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data of women with breast cancer and women without breast cancer from 54 epidemiological studies. Lancet 1996;347: Preston DL, Lubin JH, Pierce DA. EPICURE users guide. Seattle, WA: Hirosoft International, Owen-Smith V, Hannaford PC, Warskyj M, Ferry S, Kay CR. Effects of changes in smoking status on risk estimates for myocardial infarction among women recruited for the Royal College of General Practitioners oral contraception study in the UK. J Epidemiol Community Health (in press). 10 Vessey MP. The Jephcott lecture, An overview of the benefits and risks of combined oral contraceptives. In: Mann RD, ed. Oral contraceptives and breast cancer. Park Ridge, NJ: Parthenon Press, 1990: Vessey MP, Villard-Mackintosh L, McPherson K, Yeates D. Mortality among oral contraceptive users: 20 year follow up of women in a cohort study. BMJ 1989;299: Colditz GA. Oral contraceptive use and mortality during 12 years of follow-up: the nurses health study. Ann Intern Med 1994;120: Royal College of General Practitioners Oral Contraception Study. Incidence of arterial disease among oral contraceptive users. J R Coll Gen Pract 1983;33: World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic stroke and combined oral contraceptives. Haemorrhagic stroke and overall stroke risk and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996;348: World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997;349: World Health Organisation Scientific Group. Cardiovascular disease and steroid hormone contraception. WHO Tech Rep Ser 1998;877. (Accepted 15 September 1998) Key messages + This 25 year follow up of UK women found a decrease in mortality from ovarian cancer and an increase in mortality from circulatory diseases and cervical cancer among women were using oral contraceptives or had used them in the past 10 years + 10 or more years after stopping use mortality was similar in past users and never users + Oral contraceptives seem to have their main effect on mortality mainly while they are being used and in the 10 years after stopping use + There is little evidence to suggest any persistent adverse effect 10 or more years after use of oral contraceptives ceases 100 BMJ VOLUME JANUARY